You are here:
LIFE-STAGE DEPENDENT DOSIMETRY AND POTENTIAL IMPACTS ON RISK ASSESSMENT APPROACHES
Citation:
Barton, H A. LIFE-STAGE DEPENDENT DOSIMETRY AND POTENTIAL IMPACTS ON RISK ASSESSMENT APPROACHES. Presented at Society of Toxicology, New Orleans, LA, March 6-10, 2005.
Description:
Increasingly reproductive and developmental toxicity studies are utilized in assessing the potential for adverse affects in pregnant women, nursing infants, and children. These studies largely have been utilized based upon the dose to the mother due to the complexity of describing exposure doses, pharmacokinetics, and blood or tissue dosimetry of chemicals during pregnancy, lactation, and post-weaning periods. Transporters are increasingly recognized as a key factor in dosimetry during early life along with development of metabolism and other clearance processes. For pharmaceuticals, measurements of blood levels and sometimes placental and lactational transfer are addressed for safety assessment. Classical and physiologically-based pharmacokinetic analyses are increasingly being applied across these life stages. Identification of the critical window and how this period and its associated pharmacokinetics maps to humans is a significant challenge. This workshop will discuss approaches to characterizing measures of internal dose in reproductive and developmental toxicity studies and how this impacts study designs and applications for safety or risk assessment. (This abstract does not represent EPA policy)